Results 171 to 180 of about 39,486 (285)

A Delphi consensus for implementing genomic testing in unresectable or metastatic urothelial cancer

BJU International, EarlyView.
Objectives To establish a UK consensus vision of a standardised genomic testing pathway in unresectable/metastatic urothelial cancer (mUC) with clear roles and responsibilities for multidisciplinary team (MDT) members and molecular pathology laboratory teams, and to agree how the pathway must evolve to accommodate emerging innovations.
Syed A. Hussain, Amarnath Challapalli, Simran Gill, Michael Hubank, Hannah Markham, Philippe Tanière, Simon Wyatt, Robert Jones   +7 more
wiley   +1 more source

MR-Guided Radiotherapy in Oesophageal Cancer: From Principles to Practice-A Narrative Review. [PDF]

Curr Oncol
Fong SC, Lau E, Liu DS, Tebbutt NC, Khor R, Leong T, Williams D, Uribe S, Ng SP.   +8 more
europepmc   +1 more source

Longitudinal monitoring of Apparent Diffusion Coefficient (ADC) in patients with prostate cancer undergoing MR-guided radiotherapy on an MR-Linac at 1.5 T: a prospective feasibility study. [PDF]

Radiol Oncol, 2023
Almansour H, Schick F, Nachbar M, Afat S, Fritz V, Thorwarth D, Zips D, Bertram F, Müller AC, Nikolaou K, Othman AE, Wegener D.   +11 more
europepmc   +1 more source

A multi-institutional experience of MR-guided liver stereotactic body radiation therapy [PDF]

, 2019
et al,, Green, Olga L, Henke, Lauren E, Parikh, Parag J   +3 more
core   +1 more source

ADAPTIVE MR-GUIDED RADIOTHERAPY: FROM CONCEPT TO ROUTINE PRACTICE

, 2022
Radiotherapy is an established curative treatment for cancer and is also widely used in the treatment of metastatic disease. Magnetic resonance guided radiotherapy (MRgRT) represents a major treatment advance as it permits precise soft tissue setup and the continuous visualization of tumors and surrounding organs, thereby improving the safety and ...
openaire   +2 more sources

Trueness of Dental Implant Placement Using Dynamic Navigation or Non‐Guided Approach by Novice Surgeons: A Randomized, Controlled Clinical Trial

Clinical Oral Implants Research, EarlyView.
ABSTRACT Objectives To compare the trueness of implant placement in novice surgeons using dynamic computer‐assisted implant surgery (d‐CAIS) versus a non‐guided approach, assessing surgery time efficiency and patient‐reported outcomes, including satisfaction, postoperative pain, and quality of life. Material and Methods A double‐arm randomized clinical
Víctor Ruiz‐Romero, Octavi Camps‐Font, Adria Jorba‐Garcia, Alba Sánchez‐Torres, Rui Figueiredo, Eduard Valmaseda‐Castellón   +5 more
wiley   +1 more source

Evaluation of efficacy in prostate cancer contouring for MR-guided radiotherapy using structured contouring training modules. [PDF]

Tech Innov Patient Support Radiat Oncol
Fang B, Zahary Loreman H, Bayley C, Stewart C, George K, Al-Amoodi M, Jooya A, Quon H, Sia M, Lee SL.   +9 more
europepmc   +1 more source

Patient‐Reported Outcomes With Luspatercept Through 5 Years of Treatment in Patients With Non‐Transfusion‐Dependent β‐Thalassemia Treated in the BEYOND Trial

European Journal of Haematology, EarlyView.
ABSTRACT In the phase 2, double‐blind, randomized controlled BEYOND trial (NCT03342404), luspatercept increased hemoglobin levels in patients with non‐transfusion‐dependent β‐thalassemia (NTDT). This study assessed long‐term effects of luspatercept on patient‐reported outcomes (PROs), using data from BEYOND and patients who continued luspatercept ...
Khaled M. Musallam, Maria Domenica Cappellini, Antonis Kattamis, Matthew Dyer, Ahmed Hnoosh, Laurie Eliason, Christopher G. Pelligra, Shien Guo, Yutian Mu, Loyse Felber Medlin, Marta Reverte, Kevin H. M. Kuo, Ali T. Taher   +12 more
wiley   +1 more source

Long-term patient experience with online MR-guided radiotherapy: adaptive versus non-adaptive workflow. [PDF]

Front Oncol
Weykamp F, Herder-Wagner C, Regnery S, Liermann J, Meixner E, Hoegen-Saßmannshausen P, König L, Lang K, Renkamp CK, Rippke C, Klüter S, Debus J, Hörner-Rieber J.   +12 more
europepmc   +1 more source

High prevalence of loss of Claudin‐18 expression in invasive non‐mucinous lung adenocarcinoma: Potential diagnostic implications in routine practice

Histopathology, EarlyView.
Loss of Claudin‐18 (Cldn18) expression is a frequent and specific feature of non‐mucinous lung adenocarcinoma (NM‐LUAD). Cldn18 immunohistochemistry may serve as an ancillary tool for distinguishing malignant from non‐neoplastic alveolar epithelium, as well as for differentiating NM‐LUADs with mucin production from M‐LUADs, particularly in small or ...
Stefano Lucà, Marco Montella, Mario Fordellone, Riccardo Monti, Maria Giulia Disanto, Giuseppa Zannini, Marina Accardo, Maria Ali, Gaetano Di Guida, Carminia Maria Della Corte, Beatrice Leonardi, Severo Campione, Valerio Nardone, Floriana Morgillo, Alfonso Fiorelli, Luisella Righi, Mattia Barbareschi, Luka Brcic, Renato Franco   +18 more
wiley   +1 more source